#pharma intelligence

Introduction 

Pharmaceutical commercialization is a complex process that requires careful coordination between research, marketing, regulatory compliance, and market access functions. Companies must ensure that their products are not only scientifically effective but also commercially viable in highly competitive markets. To achieve this, organizations rely on structured competitive intelligence systems. One of the most important of these is Pharma CompIntel. 

Pharma CompIntel helps pharmaceutical companies collect, analyze, and interpret competitive market data to support stronger commercialization strategies. By using Pharma CompIntel, organizations can better understand competitor behavior, market trends, and customer needs. In today’s rapidly changing healthcare environment, Pharma CompIntel has become a key driver of successful pharmaceutical commercialization. 

Understanding Pharmaceutical Commercialization 

Pharmaceutical commercialization refers to the process of bringing a drug to market and ensuring its successful adoption by healthcare providers and patients. This process includes pricing, positioning, marketing, distribution, and post-launch monitoring. 

Pharma CompIntel strengthens commercialization by providing real-time insights into competitor strategies and market dynamics. Instead of relying on assumptions, companies using Pharma CompIntel can make data-driven decisions that improve product performance and market penetration. 

With increasing competition across therapeutic areas, effective commercialization has become more dependent on accurate intelligence provided by Pharma CompIntel. 

How Pharma CompIntel Improves Market Understanding 

A strong understanding of the market is essential for successful commercialization. Pharmaceutical companies must evaluate patient demand, treatment patterns, and competitor positioning before launching products. 

Pharma CompIntel helps organizations analyze these factors in detail. It provides insights into therapy trends, prescribing behavior, and healthcare provider preferences. 

By using Pharma CompIntel, companies can identify gaps in the market and position their products more effectively. This improves the likelihood of adoption and long-term commercial success. 

Competitor Insights Through Pharma CompIntel 

Understanding competitor behavior is one of the most important aspects of pharmaceutical commercialization. Companies need to know how competitors are pricing, promoting, and positioning their products. 

Pharma CompIntel allows organizations to track competitor launches, marketing campaigns, and sales performance. This intelligence helps companies adjust their own commercialization strategies in response to market changes. 

With Pharma CompIntel, pharmaceutical businesses can also identify competitor strengths and weaknesses, allowing them to develop stronger differentiation strategies. 

Pharma CompIntel and Pricing Strategy Optimization 

Pricing plays a critical role in pharmaceutical commercialization success. Companies must balance profitability with accessibility and payer expectations. 

Pharma CompIntel helps organizations analyze competitor pricing models, reimbursement policies, and market access conditions. This enables more informed pricing decisions that align with market realities. 

Through Pharma CompIntel, companies can also evaluate how pricing impacts product adoption and market share. This supports more effective commercialization planning. 

Strengthening Product Positioning with Pharma CompIntel 

Product positioning determines how a drug is perceived by healthcare providers, patients, and payers. Strong positioning is essential for commercial success. 

Pharma CompIntel provides insights into how competitors position their products and communicate value. This helps companies refine their own messaging and create stronger value propositions. 

By leveraging Pharma CompIntel, organizations can improve differentiation and ensure that their products stand out in crowded therapeutic markets. 

Pharma CompIntel in Launch Strategy Development 

Successful drug launches require detailed planning and precise execution. Companies must decide when to launch, how to position the product, and which markets to prioritize. 

Pharma CompIntel supports launch strategy development by providing insights into competitor launch timelines, promotional strategies, and early market performance. 

This intelligence helps organizations reduce launch risks and improve timing, positioning, and market entry strategies. Pharma CompIntel also supports better forecasting during pre-launch planning. 

Market Forecasting and Commercial Planning 

Accurate forecasting is essential for pharmaceutical commercialization. Companies need to estimate demand, revenue potential, and market share before and after launch. 

Pharma CompIntel improves forecasting accuracy by providing real-time insights into market trends and competitor performance. Organizations can use Pharma CompIntel to analyze prescribing behavior, treatment adoption, and therapy evolution. 

These insights help companies allocate resources more effectively and plan long-term commercialization strategies with greater confidence. 

Regulatory and Market Access Intelligence 

Regulatory approvals and market access conditions significantly influence commercialization success. Companies must stay informed about policy changes and reimbursement decisions. 

Pharma CompIntel helps organizations monitor regulatory updates, competitor approvals, and payer dynamics across global markets. This intelligence allows companies to adjust strategies quickly in response to regulatory changes. 

By using Pharma CompIntel, pharmaceutical businesses can improve compliance readiness and optimize market access strategies. 

Cross-Functional Alignment in Commercialization 

Pharmaceutical commercialization requires coordination between multiple teams, including marketing, sales, medical affairs, and regulatory departments. 

Pharma CompIntel helps improve cross-functional alignment by providing a centralized source of competitive intelligence. When all teams work with the same insights, decision-making becomes faster and more consistent. 

This alignment improves execution efficiency and ensures that commercialization strategies are implemented effectively across the organization. 

The Future of Pharma CompIntel in Commercialization 

The future of pharmaceutical commercialization is becoming increasingly data-driven. Advanced analytics, artificial intelligence, and real-time intelligence platforms are transforming how companies operate. 

Pharma CompIntel is at the center of this transformation, enabling faster, more accurate, and more strategic decision-making. Organizations can now respond to competitor actions and market changes in real time. 

As pharmaceutical markets continue to evolve, Pharma CompIntel will remain a critical tool for driving successful commercialization strategies. 

Conclusion 

Pharma CompIntel plays a vital role in strengthening pharmaceutical commercialization strategies. By providing insights into competitors, pricing, market trends, and product positioning, Pharma CompIntel helps organizations make smarter business decisions. 

Mark Timney has been president and CEO of US specialty company Purdue Pharma for just over two years but he's playing a long game to pull the business away from its single-track R&D model towards other opportunities outside pain therapy – its mainstay development area

Timney, who was previously president of Merck US but joined Purdue in January 2014, spoke with Scrip's Lucie Ellis during partnering conference BIO-Europe Spring, held in Stockholm, Sweden, April 4-6, about Purdue's interest in European partnerships and its target of achieving a transformational deal by the end of 2016 – not anywhere near oncology.

Lucie Ellis: Why is Purdue expanding its key development areas now?

Mark Timney: I was brought in to diversify the company and plan for a life after opioids, our current key portfolio area. To build this plan Purdue has fundamentally changed its business model; we are now doing less internal discovery and have instead built up a business development group so that people know what Purdue is and that we are open for business.

Purdue has a very narrow focus in abuse-deterrent opioids with extended-release formulations. While this is a tapered interest, we have been very successful. However we are going broaden our reach to the full landscape of pain therapy and then we will look at adjacencies. This will mean looking at central nervous system disorders, but we are not talking depression or schizophrenia – which are high-risk development areas – we are thinking movement disorders like Parkinson's disease, and areas like ADHA and sleep conditions. These areas are natural fits for us. Outside of CNS, based on the leadership team I have built, we can go anywhere.

[In late 2015 Purdue named ex-CEO of Panacos Pharmaceuticals and Metaphore Pharmaceuticals, Dr. Alan W. Dunton, senior vice president of R&D. Dutton is responsible for Purdue's overall scientific development strategy, including management of the pipeline, early clinical development programs and setting the scientific direction for the company. Early in the year Purdue appointed Jean-Jacques “JJ” Charhon executive vice president and chief financial officer. Charhon joined Purdue from Cnova, one of the largest global eCommerce companies, where he was also CFO.]

LE: Looking ahead then, where else would you look outside of CNS disorders?

MT: I can't give that away but I can tell you what we are not looking for. We are not interested in vaccines or large-scale primary care type businesses, and we are not looking in oncology because everyone else is there already. We are going to be driven by the asset and let the asset lead us onwards, rather than say we want to enter a pre-specified therapeutic area. This method is throwing up much more interesting ideas in science for us. If you become therapeutic area-driven you tend to go where everybody else ends up because the analysis will lead you to the same place. It's a lot more work doing it the way we are, for example: in the latest round of evaluation we have been through more than 6,000 potential assets and we are just getting to a point where we can say "Okay, we have some areas of real interest here".

LE: Why is Europe a key market for Purdue and what does the company have to offer to potential partners?

MT: Europe is really an untapped area for us as Purdue is based in, and predominantly focused on, the US. We do already have a relationship with Mundipharma, it's one of the family companies, but currently when people think Purdue they think US pain therapy company and that’s it. Events like BIO-Europe Spring acts as an introduction for us. We are looking for interesting science and late-stage assets at the moment. Purdue has very good cash flow and hope to attract someone who is looking for a commercial and development presence in the US. We have manufacturing capabilities and a very strong intellectually property group.

We also have a field force of more than 600 representatives, one of the largest specialty field forces in the industry. Furthermore, as a private company we have the ability to structure things flexibly. Europe has some great science that can be hidden and it's got some great private companies that we could work well with.

LE: Purdue has highlighted a platform deal as its preference over single assets. Why is this?

MT: We have a very broad interest at the moment. My hope is that we can find a platform to build on and add our own value too. If we find a really cool asset, I want to know that there is unmet need we can target and build a research team or research alliances around.

LE: Purdue is a private company, how is it funded now and is the company seeking more financing?

MT: We have a strong balance sheet but we are actively looking to raise funds, not out of necessity but to give me more flexibility to do the deals I want to do, when I want to do them.

LE: How is Purdue future-proofing itself as a specialty pharma?

MT: The work we are doing now is this idea exactly. I would describe Purdue at the moment as a bit of a one-legged stool because we are so narrow in our focus; I am trying to add three more legs to the stool. This will be achieved through business development because I don't believe we can get there quick enough internally. We are entering a period of investment for Purdue that will continue over the next four to five years.

Biotech firms are shifting towards M&A and away from public exits because of increasing economic pressures not sector specific challenges. Meanwhile, those struggling to secure new cash will be able to weather the storm if data and innovative research remains strong. This was the verdict from a panel discussion at partnering conference BIO-Europe Spring on keeping your head whilst navigating uncertain markets.

Adam Kostyal, senior vice president of global listing services at NASDAQ, told his audience on April 4 in Stockholm, Sweden that interest from investors for biotech IPOs remains high, but that the overall market has become cautious due to the poor performance by biotech public companies so far in 2016, particularly in the US.

"The US will pick up because we are still seeing some healthy science come out of this region," Kostyal said, adding:  "I'm expecting a turnaround in the public markets in the US by mid-year."  Kostyal also noted that the market has shifted its focus to earlier stage products and technology platforms, the combined effect causing recent IPOs to be lower in value. He expects that trend to continue.

Michele Ollier, co-founder of  Medicxi Ventures, concurred. "A lot of innovation has come out of early startups that might not have secured funding before," when pharma's focus was squarely on de-risked and established drug candidates to in-license.

Stuart Collinson, a partner at Forward Ventures, took an opposite view however, saying that though pharma has moved towards earlier-stage deals he thinks this trend will reverse itself. "I remember having conversations a few years ago that if you weren't talking about Phase III, you would struggle to get attention at all, especially enough attention to go public. It wouldn't surprise me if we see a shift back towards this way of thinking."

As for the "hot areas" currently drawing considerable attention and investment, Collinson gave gene editing as an example. "Gene editing is exciting - but not so long ago this area was almost untouchable. It remains to be seen if the data are robust enough to translate into marketed treatments for patients."

Collinson highlighted full pharma pipelines and a shrinking sector in general, as major challenges for biotechs and other healthcare startups. "As pharma continues its mega-merger activities and larger scale acquisitions, the sector goes from in-licensing to out-licensing mode."  However, pointed to large biotech businesses like Gilead Sciences and Vertex, to "pick up some of the slack," in terms of investing in and acquiring novel technologies from smaller firms.

When asked by discussion chair Adrian Dawkes, vice president of Pharma Ventures, who leads the partnering conversation , pharma or VCs, Ollier said, "Pharmas are defending their territories and acquiring assets and companies that could be a threat to their pipelines. But this means pharmas interest is in targeting assets that are far better than what they have already."

A big pharma executive in the audience noted that sometimes the industry does know what it really wants, but that good data is enough to change a company's mind. "Internal prioritization can slow novel approaches and they don't always survive internally – we need to look to outside sources," he said.

Kostyal noted duel-track IPO and M&A plans as a challenging method in the current investment environment. "There is especially very little appetite for this kind of activity in Europe," he noted. "Investors or acquirers don't understand where a biotech's commitment lies in these situations. These duel-tracks are also time consuming for a company."

Dawkes said in his view it is prudent for a company to have a backup plan for its exit strategy, but adding that it is "perhaps not cost-effective."

Collinson said, "It makes sense to keep your options open and you can do that by continually talking to big pharma. If you only target the IPO route you have to hope your inflection point lines up with a moment when the market is up."

Ollier said, "You have to keep all the doors open because younever truly know what is coming up in the near future."

China meanwhile continues to present a challenging environment, Collinson said. "China is a territory to take seriously but it's not for the faint of heart," he said. "Large emerging markets are tricky for smaller Western companies and we have even seen large pharmas, for example GlaxoSmithKline plc, make slip ups in this region."

Collinson said in this case he would argue that a strong local company might be better placed to get a drug through regulatory processes and onto the market. So out-licensing in areas like this would be his preferred method.

Get a copy of Medtrack's new report, Unpartnered Products: 2015 Update, at BIO-Europe Spring to find out which private and public life science companies have the highest number of programs ripe for partnering opportunities.

Medtrack has selected the top opportunities for partnering by narrowing down its search to private companies and public companies with less than one year of cash available (according to latest balance sheets/annual cash burn rate) with unpartnered pipeline assets.

Omeros Corporation has taken the top spot in the public sector with a total of 38 unpartnered programs in its pipeline, split as 36 preclinical assets and two Phase II opportunities. Omeros, which was previously ranked in fourth position a year earlier, is closely followed by Sarepta Therapeutics in second place. Sarepta has a total of 25 unpartnered programs, one research program, 18 preclinical assets, four Phase I candidates and two Phase II drugs. Other companies finishing off the top five in the public sector are: Skinvisible Inc (21 products), Anavex Life Sciences Corp (16), and GlobeImmune (15).

In the private sector, the company with the most unpartnered programs is Aphios Corporation, which was also ranked at number one in the previous analysis by MedTrack. Aphios has 32 unpartnered products five in research stages, 25 preclinical assets, one Phase II and one Phase III opportunity. Making up the rest of the top five for private firms is Deciphera Pharmaceuticals LLC with 27 programs, Microbiotix Inc (26), Celprogen Inc (22), and Chikujee Therapeutics (21).

In big pharma, MedTrack has looked specifically at companies with unpartnered Phase III candidates in all therapeutic areas. This field includes, Novartis' breast cancer drug BKM120 and acute myeloid leukemia therapy PKC412; Bristol-Myer's Squibb's HIV drug BMS663068; Amgen's migraine product AMG334; and Novo Nordisk's non-insulin-dependent diabetes therapy NN9535.

MedTrack analysts noted in the report that the number of big pharma out-licensing deals has almost doubled between 2010 and 2014. They highlighted Amgen's migraine drug as a potential opportunity for a neurology firm, as Amgen doesn't have neurology as a key focus area and may seek a licensee with experience in a field. However, the drug is partnered regionally with Novartis as of September 2015.

Overall, Sanofi has the most unlicensed candidates in Phase III, with 10 in total, many of which fall into the infectious disease field. Most unpartnered big pharma Phase III products belong to the infectious disease space.